Molecular targeting in radiotherapy of lung cancer

Molecular targeting is a promising option to increase the radiation response of tumours and to decrease normal tissue reactions, i.e. to achieve therapeutic gain. Molecular targeting substances in themselves are not curative while radiation is a highly efficient cytotoxic agent, with local recurrenc...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer 2004-08, Vol.45, p.S187-S197
Main Authors: Baumann, Michael, Krause, Mechthild, Zips, Daniel, Petersen, Cordula, Dittmann, Klaus, Dörr, Wolfgang, Rodemann, Hans-Peter
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - pharmacology
Animals
BBI
Biological and medical sciences
Combined Modality Therapy
COX-2
Cyclooxygenase Inhibitors - pharmacology
EGFR
Fibroblast Growth Factor 7
Fibroblast Growth Factors - pharmacology
Humans
KGF
Local tumour control
Lung Neoplasms - drug therapy
Lung Neoplasms - radiotherapy
Medical sciences
Molecular targeting
Normal tissue reactions
Pneumology
Radiotherapy
Receptor, Epidermal Growth Factor - antagonists & inhibitors
TGF-β
Transforming Growth Factor beta - antagonists & inhibitors
Translational research
Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology
Tumors of the respiratory system and mediastinum
Tumour growth delay
Tumour response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular targeting is a promising option to increase the radiation response of tumours and to decrease normal tissue reactions, i.e. to achieve therapeutic gain. Molecular targeting substances in themselves are not curative while radiation is a highly efficient cytotoxic agent, with local recurrences often occurring from only few surviving clonogenic cells. High-dose radiotherapy therefore offers optimal conditions to evaluate the potential of specific biology-driven drugs for oncology. This review summarises the current status of preclinical and clinical research on combined radiation with examples of molecular targeting substances relevant for the treatment of NSCLC (EGFR, COX-2, VEGFR, KGF, TGF-β, BBI).
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2004.07.975